Intensive gliclazide has long-lasting kidney benefits

Intensive glucose control in patients with type 2 diabetes leads to reductions in kidney failure many years after return to usual care, say Australian researchers.

Their global study shows reduced renal failure risk five and a half years after patients with type 2 diabetes ended an intensive glucose lowering regimen based on gliclazide MR.

They report less need for dialysis or transplantation without any change to the risks of death or cardiovascular disease.